Aratana Therapeutics, Inc. (PETX) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) in a research report report published on Friday, MarketBeat Ratings reports. The firm issued a buy rating and a $10.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Jefferies Group LLC set a $9.00 price target on shares of Aratana Therapeutics and gave the stock a buy rating in a research note on Thursday. Zacks Investment Research upgraded shares of Aratana Therapeutics from a hold rating to a buy rating and set a $7.75 price target on the stock in a research note on Thursday, November 9th. ValuEngine cut shares of Aratana Therapeutics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Lake Street Capital decreased their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a research note on Friday, August 25th. Finally, BidaskClub cut shares of Aratana Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $8.75.

Aratana Therapeutics (PETX) opened at $7.19 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42. Aratana Therapeutics has a one year low of $4.97 and a one year high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The company had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.47 million. During the same quarter in the previous year, the company earned ($0.38) EPS. Aratana Therapeutics’s revenue for the quarter was up 1440.0% on a year-over-year basis. research analysts forecast that Aratana Therapeutics will post -1.03 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Aratana Therapeutics, Inc. (PETX) Earns Buy Rating from Analysts at HC Wainwright” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/20/aratana-therapeutics-inc-petx-earns-buy-rating-from-analysts-at-hc-wainwright.html.

In related news, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the transaction, the chief operating officer now directly owns 70,267 shares in the company, valued at approximately $429,331.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $7.00, for a total transaction of $350,000.00. Following the transaction, the insider now owns 529,359 shares in the company, valued at $3,705,513. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 120,000 shares of company stock worth $785,600. Insiders own 5.20% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in Aratana Therapeutics by 0.6% during the 3rd quarter. Janus Henderson Group PLC now owns 1,801,381 shares of the biopharmaceutical company’s stock valued at $11,042,000 after purchasing an additional 10,551 shares during the last quarter. Alyeska Investment Group L.P. grew its holdings in Aratana Therapeutics by 10.5% during the 3rd quarter. Alyeska Investment Group L.P. now owns 964,116 shares of the biopharmaceutical company’s stock valued at $5,910,000 after purchasing an additional 91,763 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Aratana Therapeutics by 2.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 388,437 shares of the biopharmaceutical company’s stock valued at $2,381,000 after purchasing an additional 7,542 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Aratana Therapeutics by 20.8% during the 3rd quarter. Wells Fargo & Company MN now owns 367,365 shares of the biopharmaceutical company’s stock valued at $2,252,000 after purchasing an additional 63,377 shares during the last quarter. Finally, Cadence Capital Management LLC grew its holdings in Aratana Therapeutics by 5.1% during the 3rd quarter. Cadence Capital Management LLC now owns 173,808 shares of the biopharmaceutical company’s stock valued at $1,065,000 after purchasing an additional 8,449 shares during the last quarter. Institutional investors own 73.66% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply